🇺🇸 FDA
Patent

US 7943772

Crystalline forms of an 8-azabicyclo(3.2.1)octane compound

granted A61KA61K31/46A61K31/485

Quick answer

US patent 7943772 (Crystalline forms of an 8-azabicyclo(3.2.1)octane compound) held by Theravance, Inc. expires Mon May 12 2031 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Theravance, Inc.
Grant date
Tue May 17 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 12 2031 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K31/46, A61K31/485, A61K45/06, A61P